Arch Therapeutics, a life science company and developer of AC5™ for controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has named Dr. Avtar Dhillon as board chair, Dr. Arthur Rosenthal as director, and Dr. Terrence W. Norchi as president and CEO.
Dr. Dhillon has experience in company building, financing, and licensing with large industry partners, has served as the chairman of ARTH’s board of directors since April 2013, and has been on the board of directors of Arch Biosurgery, Inc. (ABS) since May 2011.
His previous employment includes the roles of president, chairman and CEO of Inovio Pharmaceuticals where he led the successful turnaround of the company through restructuring, acquisition of technology from several European and North American companies, and a merger with VGX Pharmaceuticals. Dr. Dhillon also led several successful financings for Inovio and concluded numerous licensing deals that included global giants Merck and Wyeth (now Pfizer).
Dr. Rosenthal was appointed a director of ARTH upon the completion of the company’s previously announced merger, and had been the chairman of the board of ABS since April 2011. He has 40 years of experience in senior research and product development through executive roles for medical technology companies. He has also directed commercialization efforts for hundreds of novel medical products. Dr. Rosenthal was formerly chief scientific officer at Boston Scientific and vice president of Research and Development at Johnson and Johnson Medical Products, Inc.
Dr. Norchi, on April 23, 2013, began his role with ARTH as president, CEO, and a director. Dr. Norchi has also served as the president, CEO, and director of ABS since co-founding it in 2006. He previously served as a portfolio manager and pharmaceutical analyst at Putnam Investments; senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management; and a sell-side analyst covering non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York City.
For more information, visit www.archtherapeutics.com
Let us hear your thoughts below: